An FDA advisory committee recommended six peptides, including BPC-157, for a compounding list in July 2026. That’s not the same as approval. Here’s what the vote covers and what it means if you’re considering peptide therapy.
What the FDA Actually Voted On
The FDA did not approve BPC-157. On July 23 and 24, 2026, its Pharmacy Compounding Advisory Committee (PCAC) voted on seven peptides for the agency’s 503A Bulks List. A favorable vote means the committee recommended that a peptide be added to the list. It does not establish that the peptide is safe or effective.
The 503A Bulks List controls which raw ingredients a compounding pharmacy can use for a personalized prescription. That’s different from FDA review of a finished drug like semaglutide, the active ingredient in Ozempic and Wegovy.
A recommendation, inclusion on the list, and FDA approval are three different things, and none of them prove a peptide actually works for what people are using it for.
What the Committee Actually Voted On
The committee considered seven substances over two days. Six got a favorable recommendation. One did not.
Official FDA minutes containing the vote counts have not yet been published. The reported tallies for BPC-157, KPV, TB-500, MOTS-C, and Emideltide were consistent across AJMC, RAPS, and McDermott Will & Emery. Reported counts for Semax and Epitalon varied slightly by source, so this table uses the figures reported most consistently. We will update the table with the official vote counts when they become available.
Why the Vote Is More Complicated Than “Peptides Work”
FDA’s own staff actually proposed rejecting all seven substances, not just the one the committee later voted down, a detail most coverage skipped. Its briefing document raised the same concerns for nearly every peptide: little or no human evidence, trials that were small and short, and inconsistent identification of what’s actually sold under each name.
Why did the committee recommend six anyway? Not because the evidence improved. During the discussion, committee member Bill Zamboni said, “There are too many unknowns about this product.” Fellow member David Pope reached the opposite conclusion from that same uncertainty. He argued the decision belongs with the physician and pharmacist treating an individual patient, not a federal list.
That uncertainty cuts both ways. Patients are already seeking these peptides through unregulated online markets with no quality control, and keeping a substance off the list doesn’t stop that demand. It just pushes it somewhere with less oversight.
FDA staff disagreed. In their view, a favorable vote doesn’t create better evidence, and it can even reduce the incentive to run the trials that would. Neither side won that argument. The real story is the unresolved tension between limited evidence and real patient demand, and the FDA still hasn’t settled it.
What Does the Evidence Actually Show?
A recommendation from the committee should not be confused with proof that a treatment works. The available research varies considerably among the six substances, and for several of them, important questions remain unanswered.
BPC-157 has attracted significant attention for its potential role in joint and soft-tissue recovery, but most of the supporting research comes from animal studies. To date, no peer-reviewed human clinical trial has established that it provides those benefits in people.
The evidence for KPV is even earlier in its development. Laboratory and animal studies have explored its effects on inflammation involving the gut and skin, but that research does not establish its effectiveness for joint pain. Human clinical trials have not yet been published.
TB-500 presents a different problem. Much of the research commonly associated with it examines thymosin beta-4, the full-length molecule, rather than the shorter fragment marketed as TB-500. A 2026 scoping review identified only one study directly involving the TB-500 fragment. That distinction matters because findings about thymosin beta-4 cannot automatically be applied to the TB-500 products patients may encounter.
What Happens Next in the Regulatory Process
If the FDA moves forward, it runs formal rulemaking: a proposed rule, public comments, then a final rule. There’s no deadline. A similar process once took more than two years, though the FDA can move faster when it prioritizes an issue. The Department of Health and Human Services, which oversees the FDA, has signaled support for expanding peptide access. A statement of support isn’t a completed rule.
In the meantime, state pharmacy boards, not the FDA, still regulate compounding day to day. Truth-in-advertising rules still apply too. No one can call a compounded peptide “clinically proven” just because a committee voted yes.
What This Means If You’re Considering Peptide Therapy
None of this takes peptide therapy off the table. It means asking the same questions you’d ask about any treatment where the research is still developing.
- What are you trying to address, and does the evidence, human or animal, actually speak to that goal?
- What’s known about the risks, and what’s simply unknown?
- Where does the peptide come from, and does that source test for identity and purity?
- Could your current medications or conditions change how you respond?
- Who’s checking in on your response, and adjusting the plan if needed?
A licensed provider does something a research-chemical vendor can’t. At Dynamis, a personalized protocol starts with a full hormone panel and health history, built by board-certified providers through licensed U.S. pharmacies.
Dynamis currently works with several peptides from this FDA meeting: BPC-157 (injection and capsule), KPV, TB-500, the combined BPC-157/KPV/TB-500 formulation, MOTS-C, and Semax as part of the Semax/Selank spray. Availability isn’t a recommendation that any of them is right for you. Your health coach and provider decide that together, based on your labs, and adjust as you respond.
Find Out Whether Peptide Therapy Fits Your Goals
Interest in peptides is moving faster than the research behind several of them. A Dynamis provider can review your health history and goals, walk you through what the evidence does and doesn’t support, and help you decide if a personalized protocol makes sense, before you spend money on a product no one is checking.
Frequently asked questions
Can You Legally Buy BPC-157 Online Right Now?
BPC-157 is advertised for sale online, but that does not mean those products are legally authorized for human use. BPC-157 is not an FDA-approved drug, and the advisory committee’s recommendation did not approve it, add it to the 503A Bulks List, or authorize its general sale as a medication. Products labeled as “research chemicals” should not be purchased or used for self-treatment. Patients considering BPC-157 should speak with a licensed provider and verify that any prescribed product comes from a properly licensed pharmacy operating under current federal and state compounding rules.
Does Dynamis offer Epitalon?
No. Epitalon is the one peptide from this meeting that Dynamis doesn’t currently carry. Dynamis works with BPC-157, KPV, TB-500, the BPC-157/KPV/TB-500 combination, MOTS-C, and Semax as part of the Semax/Selank spray.
Did the FDA approve BPC-157 in 2026?
No. The July 2026 vote was a recommendation from the FDA’s Pharmacy Compounding Advisory Committee to add BPC-157 to the 503A Bulks List. It was not FDA approval of BPC-157 as a drug, and the recommendation does not establish its safety or effectiveness.
Which peptides did the FDA advisory committee recommend?
The committee recommended six peptides: BPC-157, KPV, TB-500, MOTS-C, Semax, and Epitalon. Emideltide (DSIP) was the only substance considered at the July 2026 meeting that did not receive a favorable recommendation.
What happens after the FDA peptide vote?
The committee’s recommendation does not immediately change the regulatory status of these peptides. If the FDA moves forward, the agency must go through the rulemaking process before substances are formally added to the 503A Bulks List. There is no set deadline for that process.
